{"id":"W3026097555","doi":"10.1016/j.jval.2020.04.1618","title":"PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Discontinuation; Fulvestrant; Adverse effect; Internal medicine; Breast cancer; Placebo; Oncology; Cancer; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001750419,0.0006040205,0.001199138,0.0005960569,0.0003308872,0.001591634,0.0009164202,0.0007353738,0.006876329],"category_scores_gemma":[0.004550672,0.0002167426,0.001920499,0.001076236,0.0005644422,0.0005667069,0.0004836566,0.00155431,0.0002489672],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02290025,"about_ca_system_score_gemma":0.02392771,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5777519,"about_ca_topic_score_gemma":0.7278813,"domain_scores_codex":[0.9990559,0.0003673013,0.00003738293,0.00006430586,0.0002526256,0.0002224961],"domain_scores_gemma":[0.9988613,0.0003784613,0.000137527,0.00002718428,0.0002104935,0.0003849959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.1261921,0.0018181,0.01865893,0.003921407,0.00632312,0.0004587893,0.0001807072,0.09811927,0.003156965,0.02051677,0.0527458,0.6679081],"study_design_scores_gemma":[0.1131442,0.0517564,0.4101789,0.01018923,0.03353409,0.001623112,0.002193755,0.1661599,0.005460179,0.03002053,0.1749124,0.0008273353],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.720605,0.1407936,0.002832504,0.03883333,0.001228361,0.001129112,0.01444558,0.0001632414,0.07996927],"genre_scores_gemma":[0.9760114,0.01484903,0.00160055,0.001179297,0.0001851081,0.00009304056,0.002802395,0.00001693606,0.003262367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9770998,"threshold_uncertainty_score":0.8494697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2336847063129549,"score_gpt":0.3999543408166003,"score_spread":0.1662696345036454,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}